Abiopharma

🔍 Mehta Vikas D (Executive)

Company: Remitly Global, Inc. (RELY)

Report Date: 2026-04-29

Detailed Transactions and Holdings:

• Acquired 30,887 shares of Common Stock (Direct)
  Date: 2026-04-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 893,646.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 138,628 shares of Common Stock (Direct)
  Date: 2026-04-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,032,274.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents a grant of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest as to 1/2 of the total shares underlying the RSUs on May 25, 2026, and then 1/2 of the total shares vest quarterly thereafter, subject to the reporting person's provision of service to the Issuer on each vesting date.
• F2: Represents a grant of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest as to 1/4 of the total shares underlying the RSUs on May 25, 2029, and then 1/4 of the total shares vest quarterly thereafter, subject to the reporting person's provision of service to the Issuer on each vesting date.